Nov 11, 2021 06:19 AM

China Moves Closer to Clearing mRNA Vaccines as Covid Booster Shots

China has approved seven domestically developed Covid-19 vaccines for public inoculation
China has approved seven domestically developed Covid-19 vaccines for public inoculation

Chinese regulators took a step toward clearing the use of mRNA vaccines as booster shots to protect against Covid-19.

An mRNA vaccine jointly developed by Chinese biotech company Walvax Biotechnology Co. and Suzhou Abogen Biosciences won administrative approval to conduct a Phase 3b clinical trial of the shot, Walvax told Caixin. Approval was granted to assess the efficacy and safety of using the mRNA vaccine as booster shots for adults inoculated with inactivated-virus vaccines, according to public records on the Ministry of Science and Technology website.

MRNA vaccines have shown higher efficacy as booster shots than inactivated-virus shots, Zeng Guang, former chief epidemiologist of the Chinese Center for Disease Control and Prevention, said earlier this week. Zeng cited studies by Turkey’s Yeditepe University that an mRNA booster after two shots of inactivated-virus vaccines would boost IgG-S antibodies by 46.6 times, compared with 1.7 to 1.8 times by a third shot of inactivated-virus vaccine.

No mRNA-based Covid-19 vaccine has been approved so far in China, although the advanced vaccine technology has been widely used in the West. Several domestic companies are racing to deliver shots using it. Walvax and partner Suzhou Abogen are the front-runners among domestic players. Germany’s BioNTech and its Chinese partner Shanghai Fosun Pharmaceutical Co. Ltd. are conducting final-stage tests of its widely used mRNA vaccine to launch in China.

News about the Walvax approval drove up the company’s Shenzhen-traded shares by as much as 20% Wednesday. Fosun Parma also jumped nearly 10% in Hong Kong.

Drugmakers often divide Phase 3 trials of new medicines into two steps. Companies can apply for marketing approval after completion of a Phase 3a trial, while a Phase 3b trial further tests a drug’s indications and other key clinical features. It still takes several months for a new drug to win final marketing approval.

The Phase 3b trial was filed by the Disease Control and Prevention Center in the Guangxi Zhuang Autonomous Region in southern China, according to the Ministry of Science and Technology website. The trial will cover people ages 18 to 59 as well as those older than 60, according to the records.

Under a plan published by Walvax in July, the Phase 3 trial of its mRNA vaccine, known as ARCoV-005, could be carried out in several counties in Guangxi and the southwest province of Yunan until Nov. 30, involving 1,500 in the vaccinated group and 500 in a placebo group. Walvax said it launched Phase 3 clinical trials for ARCoV-005 in countries including China, Mexico, Indonesia and Nepal.

China has approved seven domestically developed Covid-19 vaccines for public inoculation, including five inactivated-virus shots, one recombinant adenovirus vector vaccine and one based on recombinant subunit protein technology.

The Chinese mainland has vaccinated nearly 80% of its more than 1.4 billion people and has started offering booster shots to people in several provinces and cities as new outbreaks of the delta mutation spread.

In Hong Kong, a third shot will be offered starting Nov. 11, with local health authorities recommending mRNA vaccines as boosters.

Contact reporter Han Wei ( and editor Bob Simison (

Download our app to receive breaking news alerts and read the news on the go.

Get our weekly free Must-Read newsletter.

You've accessed an article available only to subscribers
Share this article
Open WeChat and scan the QR code
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
Caixin Biz Roundup: China’s Covid Caseload Hits Six-Month High